New publication: CHANTER is an under-recognized syndrome of multifocal cerebral edema after opioid ingestion. It's important to recognize: diffusion restriction and edema are reversible and outcomes are promising! Free copy: tinyurl.com/2s468pz4 Dan Harrison, MD Brigham and Women’s Neurocritical Care

Author David Seiffge discusses "Location and Timing of Recurrent, Nontraumatic Intracerebral Hemorrhage" with JAMA Neurology Web Editor Cynthia Armand. ja.ma/3Xpfktu

EURECA: New data on recurrent ICH: every second recurrence is adjacent to index ICH. Those bleedings occur early and are strongly associated with CAA. Great collaboration lead by Martina Göldlin Stroke Research Center Bern Author interview podcast: edhub.ama-assn.org/jn-learning/au… jamanetwork.com/journals/jaman…

Amazing international multi-cohort collaboration just published JAMA Neurology Thanks Martina Göldlin David Seiffge for the amazing work and opportunity to be part of this great work!

A STOP-CAD secondary analysis engineered by Daniel Mandel, MD : Among high risk features identified in cervical artery dissection, only occlusive dissection seemed to benefit from anticoagulation. Important information for future trials. ahajournals.org/doi/full/10.11… Stroke AHA/ASA 🛑CAD

BREAKING from NEJM In cancer patients w/ Cancer-Associated Venous Thromboembolism, reduced-dose apixaban (2.5 mg BID) is : 🔘Noninferior to full-dose (5 mg BID) for VTE recurrence 🔘Lower bleeding risk (12.1% vs. 15.6%) 🔘Safer extended anticoagulation, same protection.

🚨Neuroprotective agents in Large Core Strokes 👉🏻 Edaravone + Dexborneol vs usual care 👉🏻 < 14 days of onset ✅ drugs: better functional outcomes at 90 days and trend to lower mortality

#ESOC2025 🧠Covert Brain Infarction ⬆️Increase risk of Stroke ~2x 📈More CBI, more risk ☝️Inform the patient 🚭Treat risk factors Erasmus MC

#ESOC2025 | The OPTIMIST trial suggests low-intensity monitoring after IV thrombolysis in mild to moderate stroke can deliver comparable safety & outcomes to standard protocols—while easing ICU strain & improving patient experience 📍4922 patients | 114 hospitals | 8 countries

Presented at #ESOC2025: Among 550 patients with stroke due to large-vessel occlusion who had presented within 4.5 hours after onset, 90-day functional outcomes were better with intravenous tenecteplase before thrombectomy than with thrombectomy alone. Read the full BRIDGE-TNK

#ESOC2025 ✅ASSET-IT: early tirofiban after IVT 👉🏻>mRS 0-1 and 0-2 at 90 day in Tirofiban arm 👉🏻 = sICH and mortality al 90 days

Presented at #ESOC2025: Tirofiban, an IV antiplatelet, given as an adjunct to IVT, improved the odds of excellent functional outcome in patients with AIS, at the cost of an increased risk of intracranial bleeding in the ASSET-IT trial #VoiceOfStroke

BRIDGE TNK trial presented at #ESOC2025 shows superior outcomes with IV Tenecteplase + thrombectomy vs thrombectomy alone in acute LVO stroke within 4.5h 🧠 Functional independence - mRS 0–2 🟦 52.9% with bridging vs 44.1% thrombectomy 🧾 Adjusted RR 1.18 #StrokeTreatment

New DISTAL Trial sub-analysis: Endovascular therapy boosted chances of saving at least 80% of affected brain tissue in medium distal vessel occlusion stroke. Preservation of ≥80% of at-risk brain tissue significantly improved outcomes. Tissue saved = better recovery #ESOC2025

#ESOC2025 🏃🏻‍♀️ESCAPE MEVO sub analysis 👉🏻 prognosis by image 🧠 👉🏻EVT <12 hs not > good functional outcome 👉🏻 Good collateral status > benefit 👉🏻 ⏱️<180 min > benefit

🚨EXCOA-CVT trial at #ESOC2025:Extending oral anticoagulation after cerebral vein thrombosis shows no clear benefit vs. short-term use. Both VTE recurrence & bleeding rates low. Individualised treatment decisions are key! #Stroke #CVT #VoiceOfStroke #StrokeTwitter Diana Aguiar de Sousa

The "first" subanalysis from the Distal Trial is disclosed by Aikaterini Anastasiou, with results across 447 patients suggesting a higher proportion of brain tissue being saved in the study's EVT group compared to its best medical therapy group #esoc2025 European Stroke Org Marios Psychogios

🚨 Keynote Alert at #ESOC2025! GOLDEN BRIDGE II shows AI-driven clinical decision support can improve stroke recurrence rates without safety hazards in acute ischemic stroke care. 📍22 May | Helsinki 👥 21,600+ patients, 77 hospitals #Stroke #AI #ClinicalTrials

ESTREL trial at #ESOC2025: Levodopa did not boost motor recovery after stroke, but extensive ESTREL data may pave the way for exciting advances in personalized rehabilitation. The awakening of stroke rehabilitation might just be postponed! #Stroke #Rehab

#STROKE: In a secondary analysis of ARCADIA, randomization to apixaban was associated with a lower risk of recurrent ischemic stroke than aspirin in patients with left ventricular systolic dysfunction. Mitchell Elkind Hooman Kamel Shadi Yaghi #AHAJournals ahajrnls.org/42Qu1bM